HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
India has taken the lead in recognising NAFLD as a major non-communicable disease
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
